Biotech | October 07, 2021
Moderna to build mRNA facility in Africa
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
This is the first time in South Asia an indigenously made drone was used to transport Covid-19 vaccines
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
It is a recombinant nanoparticle protein-based vaccine
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
In India, almost all approved vaccines are packed in FIOLAX glass made by SCHOTT
Subscribe To Our Newsletter & Stay Updated
